GTCR to Buy Drugmaker Zentiva from Advent in $4.8 Billion Deal

Buyout firm GTCR agreed to acquire generic drugmaker Zentiva Group AS from Advent, adding to a flurry of health-care deals this year.

The transaction is expected to be completed by early 2026, according to a statement on Thursday that confirmed an earlier Bloomberg News report. Zentiva is valued at about $4.8 billion in the transaction, people familiar with the matter have said.